Effects of bunazosin and atenolol on serum lipids and apolipoproteins in a randomised trial.
The effects of bunazosin and atenolol on serum lipids and lipoproteins after 6 months of treatment were compared in this multicentric, double-blind, randomised trial. A total of 174 patients with mild to moderate essential hypertension from 15 hospitals in Germany and Poland was included in the study. Eighty-seven were treated with the alpha-receptor blocker bunazosin and the same number with the beta-blocker atenolol. Systolic and diastolic blood pressure decreased significantly in both groups, whereas only atenolol decreased pulse rate. In the bunazosin group HDL-cholesterol was significantly increased after 6 months of treatment, whereas all other analysed parameters remained unchanged. In the atenolol group total cholesterol, LDL-cholesterol, total triglycerides, apolipoprotein E, VLDL-cholesterol and VLDL-triglycerides were significantly increased after 6 months of therapy. There was a significant difference between bunazosin and atenolol for total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol, triglycerides, VLDL-triglycerides and apolipoprotein B levels. As a consequence, there was a significant difference in the atherogenic index of both groups. We conclude that bunazosin is favorable in the treatment of high blood pressure, because the coronary risk is not negatively influenced as shown for atenolol.
Schmitz
G
G
Institut für Klinische Chemie und Laboratoriumsmedizin, Universität Regensburg, Germany.
Stumpe
K O
KO
Herrmann
W
W
Weidinger
G
G
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001053:Apolipoproteins / Q000097:blood*; D001262:Atenolol / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000008:administration & dosage*; D016896:Treatment Outcome
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D001053:Apolipoproteins; D008055:Lipids; D011799:Quinazolines; D001262:Atenolol; C018176:bunazosin